Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Gains from Sales and Divestitures (2022 - 2025)

Abeona Therapeutics (ABEO) has 4 years of Gains from Sales and Divestitures data on record, last reported at $1.4 million in Q3 2025.

  • For Q3 2025, Gains from Sales and Divestitures rose 43.25% year-over-year to $1.4 million; the TTM value through Sep 2025 reached $1.4 million, up 43.25%, while the annual FY2024 figure was $1.0 million, 273.05% up from the prior year.
  • Gains from Sales and Divestitures reached $1.4 million in Q3 2025 per ABEO's latest filing, up from $500780.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.4 million in Q3 2025 and bottomed at $27526.0 in Q4 2022.
  • Average Gains from Sales and Divestitures over 4 years is $567534.2, with a median of $500780.0 recorded in 2025.
  • Peak YoY movement for Gains from Sales and Divestitures: soared 882.89% in 2023, then crashed 38.84% in 2025.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $27526.0 in 2022, then skyrocketed by 882.89% to $270550.0 in 2023, then soared by 273.05% to $1.0 million in 2024, then skyrocketed by 38.26% to $1.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $1.4 million in Q3 2025, $500780.0 in Q2 2025, and $68167.0 in Q1 2025.